Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 25-33

  Johnsson, Anders ^a   Höglund, Peter ^a   Grubb, Anders ^a   Cavallin Ståhl, Eva ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CDDP; CDDP DNA adducts; Nephrotoxicity; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; CISPLATIN; FLUOROURACIL; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CHEEK; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DNA BINDING; DRUG BLOOD LEVEL; DRUG METABOLISM; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; MALE; NEPHROTOXICITY; POPULATION MODEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA ADDUCTS; ESOPHAGEAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY TUBULES; MALE;

EID: 0029822505     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050534     Document Type: Article

References (34)

1. Beal SL, Sheiner LB (1980) The NONMEM system. Am Stat 34:118
2. Beal SL, Sheiner LB (1982) Estimating population kinetics. CRC Crit Rev Biomed Eng 8 : 195
3. Blommaert FA, Michael C, Terheggen PMAB, Muggia FM, Kortes V, Schornagel JH, Hart AAM, Engelse L den (1993) Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 53 : 5669
4. Campbell AB, Kalman SM, Jacobs C (1983) Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 67 : 169
5. Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick -Bruton F, Muggia FM, Reed E (1992) Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ Health Perspect 98 : 53
6. Daley-Yates PT, McBrien DCH (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 33 : 3063
7. Daugaard G, Rossing N, Rørth M (1988) Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high dose. Cancer Chemother Pharmacol 21 : 163
8. Desoize B, Marechal F, Millart H, Cattan A (1991) Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. Biomed Pharmacother 45 : 203
9. Desoize B, Dumont P, Manot PL, Urien S, Dufour R, Berthiot G (1994) Comparison of two dose prediction models for cisplatin. Anticancer Res 14: 2285
10. Fichtinger-Schepman AMJ, Oosterom AT van, Lohman PHM, Berends F (1987) cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diammine-dichloroplatinum(II). Cancer Res 47 : 3000
11. Fichtinger-Schepman AMJ, Velde-Visser SD van der, Dijk-Knijnenburg WCM van, Oosterom AT van der, Baan RA, Berends F (1990) Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissues of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 50 : 7887
12. Fish RG, Shelley MD, Badman J, Mason M, Paterson I (1994) Platinum accumulation in adult cancer patients receiving cisplatin. Plasma and urinary platinum concentrations on first drug exposure. Drug Invest 7 : 175
13. Gamelin E, Allain P, Maillart P, Turcant A, Delva R, Lortholary A, Larra F (1995) Long-term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother Pharmacol 37 : 97
14. Grubb A (1992) Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 38 : S20
15. Grubb A (1992) Zur empfindlichen und schnellen Klassifizierungen der Proteinurie: Analyse einzelner Proteine im Urine. Diagn Lab 42 : 157
16. Hofmann W, Rossmüller B, Guder WG, Edel HH (1992) A new strategy for characterizing proteinuria and haematuria from single pattern of defined proteins in urine. J Clin Chem Clin Biochem 30 : 707
17. Johnsson A, Olsson C, Andersson H, Cavallin-Ståhl E (1994) Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice. Cytometry 17 : 142
18. Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Ståhl E (1995) Pharmacokinetics and tissue distribution in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 37 : 23
19. Kelland LR (1994) The molecular basis of cisplatin sensitivity/resistance. Eur J Cancer 30A : 725
20. Kelsen DP, Alcock N, Young CW (1985) Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations. Am J Clin Oncol 8 : 77
21. Leone R, Fracasso ME, Soresi E, Cimino G, Tedeschi M, Castoldi D, Monzani V, Colombi L, Usari T, Bernareggi A (1992) Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol 29 : 385
22. Manaka RC, Wolf W (1978) Distribution of cisplatin in blood. Chem Biol Interact 22 : 353
23. Patton TF, Repta AJ, Sternson LA, Belt RJ (1982) Pharmacokinetics of intact cisplatin in plasma. Infusion versus bolus dosing. Int J Pharm 10 : 7
24. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmès P (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35 : 1
25. Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafiltrable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafiltrable platinum plasma levels and nephrotoxicity. J Clin Oncol 5 : 304
26. Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC (1990) Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 50 : 2256
27. Schellens JHM, Ma J, Planting AST, Burg MEL van der, Schmitz PIM, Stoter G, Verweij J (1995) Exposure to cisplatin and WBC DNA-adduct formation determine the likelihood of response in solid tumor patients, which enables adaptive intrapatient dose-escalation. Proceedings, 7th international symposium on platinum and other metal coordination compounds in cancer chemotherapy, Amsterdam, March 1-4, 1995, p 55
28. Stewart DJ, Benjamin RS, Zimmerman S, Caprioli R, Wallace S, Chuang V, Calvo III D, Samuels M, Bonura J, Li Loo T (1983) Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res 43 : 917
29. Sunderman FW Jr, Sporn J, Hopfer SM, Sweeney KR, Chakraborty NG, Greenberg B (1990) Platinum in blood mononuclear cells from patients after cisplatin therapy. Ann Clin Lab Sci 20 : 379
30. Tencer J, Thysell H, Andersson K, Grubb A (1994) Stability of albumin, protein HC, immunoglobulin G, kappa- and lambda-chain immunoreactivity, orosomucoid and alpha 1-antitrypsin in urine stored at various conditions. Scand J Clin Lab Invest 54 : 199
31. Terheggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman AMJ, Engelse L den (1987) Immunocytochemical detection of interaction products of cis-diammindichloroplatinum(II) and cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) with DNA in rodent tissues. Cancer Res 47 : 6719
32. Terheggen PMAB, Dijkman R, Begg AC, Dubbelman R, Floot BGJ, Hart AAM, Engelse L den (1988) Monitoring of interaction products of cis-diammindichloroplatinum(II) and cis-diammine (1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated patients. Cancer Res 48 : 5597
33. Vermorken JB, Vijgh WJF van der, Klein I, Hart AAM, Gall HE, Pinedo HM (1984) Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep 68 : 505
34. Vermorken JB, Vijgh WJF van der, Klein I, Gall HE, Groeningen CJ van, Hart GAM, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39 : 136